The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

The first two groups included 36,082 patients using GLP-1 receptor agonists and 234,028 patients using DPP-4 inhibitors ...

However, both GLP-1s and SGLT2 inhibitors may offer similar antidepressant benefits, researchers noted. The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older ...

The first cohort comprised individuals who started and continued either a GLP-1 receptor agonist or DPP-4 inhibitor for the first time between January 1, 2007, and December 31, 2020. The second ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

In one arm of the study, researchers compared more than 36,000 people prescribed a GLP-1 drug against more than 234,000 patients taking DPP-4 inhibitors for their diabetes between 2007 and 2020.

and colleagues compared the risk for depression in older adults with T2D initiating treatment with GLP-1 RAs versus sodium-glucose cotransporter-2 inhibitors (SGLT-2is) or DPP-4is in a target ...

Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

Investigators evaluated dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and SGLT2 inhibitors to determine if differences in efficacy are associated ...

Compared with currently available insulin secretagogues, DPP-4 inhibitors, by enhancing biologically active (intact) GLP-1, increase insulin secretion and suppress glucagon secretion in a glucose ...